Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026)
Verano Holdings' (VRNO) quarterly Income from Continuing Operations came in at 17823000.0 in Q1 2026, down 54.78% year-on-year from 39414604.38 in Q1 2025, and up 90.28% on a QoQ basis from 183411000.0 in Q4 2025.
Verano Holdings (VRNO) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Income from Continuing Operations data on file, last reported at 17823000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 54.78% year-over-year to 17823000.0 in Q1 2026; TTM through Mar 2026 was 264216000.0, a 24.2% increase from a year earlier, with the FY2025 full-year figure at 257908000.0, up 24.56% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 17823000.0, up from 183411000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for VRNO reached as high as 45866000.0 in Q1 2022 and fell as low as 272706000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 56354235.29 across 5 years, with a median of 19150000.0 in 2025.
- On a YoY basis, Income from Continuing Operations climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
- Year by year, Income from Continuing Operations stood at 216110000.0 in 2022, then soared by 64.24% to 77286000.0 in 2023, then sank by 252.85% to 272706000.0 in 2024, then jumped by 32.74% to 183411000.0 in 2025, then soared by 90.28% to 17823000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 17823000.0 in Q1 2026, 183411000.0 in Q4 2025, and 43832000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | -17.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.82 Mn |
| Dec 31, 2025 | -183.41 Mn |
| Sep 30, 2025 | -43.83 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -11.52 Mn |
| Dec 31, 2024 | -272.71 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -21.76 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -77.29 Mn |
| Sep 30, 2023 | -17.76 Mn |
| Jun 30, 2023 | -13.06 Mn |
| Mar 31, 2023 | -9.24 Mn |
| Dec 31, 2022 | -216.11 Mn |
| Sep 30, 2022 | -42.99 Mn |
| Jun 30, 2022 | -9.85 Mn |
| Mar 31, 2022 | 45.87 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -11.96 Mn |
| Jun 30, 2021 | -29.59 Mn |